Is IDEAYA Biosciences, Inc. (IDYA) a Buy, Sell, or Hold?
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$36.65 USD
$0.5 (1.38%)
- Volume
- 1.21M
- Average Volume
- 1.24M
- Market Capitalization
- $3.48B
- P/E Ratio
- -23.20
- Dividend Yield
- 0.00%
- Price Target
- $58.00
- Year High
- $40.58
- Year Low
- $21.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.74
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yujiro S. Hata |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IDYA |
| CUSIP | 45166A102 |
| CIK | 0001676725 |
| Web | https://www.ideayabio.com |
| Phone | 650 443 6209 |
| Currency | USD |
| Employees | 145 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.74 |
| Quick Ratio | 10.74 |
| Cash Ratio | 2.43 |
Sales & Book Value
| Annual Sales | $218.71M |
| Price / Sales | 15.47 |
| Cash Flow | -0.99 |
| Price / Cash Flow | -39.63 |
| Price / Book | 3.47 |
Price Target and Rating
| Average Stock Price Forecast | $58.00 |
| High Stock Price Forecast | $63.00 |
| Low Stock Price Forecast | $48.00 |
| Forecast Upside/Downside | -36.81% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.28 |
| Trailing P/E Ratio | -23.20 |
| PEG Ratio | -0.53 |
| P/E Growth | -0.53 |
| Net Income | $-113.7M |
| Net Margin | -62.17% |
| Pretax Margin | -62.17% |
| Return on Equity | -13.96% |
| Return on Assets | -13.59% |
Financials Score
| AltmanZ Score | 21.53 |
| Piotroski Score | 3.00 |
| Working Capital | 631.28M |
| Total Assets | 1.03B |
| Ebit | -140.06M |
| Market Cap | 3.44B |
| Total Liabilities | 93.08M |
Poll Results
About IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA ... 's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-06-26 06:00:00
SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 25, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 98,000 shares of the Company's common stock to four newly hired employees.
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
2026-06-17 06:00:00
SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S.
2026-06-15 06:00:00
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) SOUTH SAN FRANCISCO, Calif.
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
2026-06-11 03:22:42
IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM, supporting an RTOR NDA Accelerated Approval submission filing. Upcoming catalysts include NDA filing submission completion of darovasertib in H2 2026, label expansion data for HLA*A2-positive mUM, and further neoadjuvant/adjuvant melanoma updates.
2026-06-10 16:05:00
SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 5,555,576 shares of common stock at a public offering price of $26.9999 per pre-funded warrant, before underwriting discounts and commissions.
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
2026-06-08 23:00:00
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
2026-06-08 22:22:00
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-08 16:01:00
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.
Frequently Asked Questions
-
What is the current IDEAYA Biosciences, Inc. (IDYA) stock price?
-
IDEAYA Biosciences, Inc.(NASDAQ:IDYA) stock price is $36.65 in the last trading session. During the trading session, IDYA stock reached the peak price of $40.58 while $21.33 was the lowest point it dropped to. The percentage change in IDYA stock occurred in the recent session was 1.38% while the dollar amount for the price change in IDYA stock was $0.5.
-
IDYA's industry and sector of operation?
-
The NASDAQ listed IDYA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IDYA?
-
Douglas Snyder | Chief Legal Officer
Andres Ruiz Briseno | Chief Accounting Officer
Yujiro S. Hata | Founder, President, CEO & Chairman
Joshua Bleharski | Chief Financial Officer
Darrin Beaupre | Chief Medical Officer -
How many employees does IDYA have?
-
Number of IDYA employees currently stands at 145. IDYA operates from 7000 Shoreline Court, South San Francisco, CA 94080, US.
-
Link for IDYA official website?
-
Official Website of IDYA is: https://www.ideayabio.com
-
How do I contact IDYA?
-
IDYA could be contacted at phone #650 443 6209 and can also be accessed through its website. IDYA operates from 7000 Shoreline Court, South San Francisco, CA 94080, US.
-
How many shares of IDYA are traded daily?
-
The average number of IDYA shares traded daily for last 3 months was 1.24M.
-
What is the market cap of IDYA currently?
-
The market value of IDYA currently stands at $3.48B with its latest stock price at $36.65